KUALA LUMPUR: Malaysian Genomics Resource Centre Bhd
's wholly-owned subsidiary MGRC Therapeutics Sdn Bhd has entered into a collaboration with South Korea-listed Dx&Vx Co Ltd to drive the development and supply of advanced genomic testing services.
It said MGRC Therapeutics will leverage its extensive expertise in genomics and biopharmaceuticals to support the operational and technical aspects of the genomic testing services.
Concurrently, DxVx, a prominent healthcare solutions provider based in South Korea, will provide its cutting-edge “GenomeCheck” solutions and technical consultancy to enhance the service offerings.
"Partnering with Dx&Vx Co Ltd is a strategic move that will elevate our genomic testing services to new heights.
"By combining our strengths, we are set to enhance the precision and accessibility of genomic analysis, making significant strides in personalised medicine,” said Malaysian Genomics.
